Drugs / 5-hidroxitriptophan
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05401032 | Dec 2024 → Dec 2026 expected | benign prostatic hyperplasia | Clinical Academic Center (2CA-Braga) | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 5-hidroxitriptophan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05401032 ↗ |
| Known as | 5-HTP | “5-HTP (5-hidroxitriptophan) 100mg (three times a day, t.i.d.)” NCT05401032 ↗ |
| Route | Oral | “Oral medication, 3 times a day for 6 months.” NCT05401032 ↗ |